type I and III IFNs

[키워드] absence accompanied adaptive immune responses Anti-viral anti-viral IFN anti-viral response antiviral responses Asymptomatic asymptomatic SARS-CoV-2 infected subjects Cell cells cellular characterized chemokine chemokines circulating contribute coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pathogenesis COVID-19 patient Critically ill Critically ill patient critically ill patients cytokine Cytokine storm Cytokines death Defense dendritic cell dendritic cells disease severity early phase elevated ENhance epithelial cells event Evidence Ex vivo expression fine-tune Frequency hospitalized patient hospitalized patients Host host defense Host-directed therapies host-directed therapy human peripheral blood mononuclear cell IFN IFN-stimulated gene Immune cell immune cells immune responses Immunity IMPROVE in vitro induce Infection Inflammatory cytokine Inflammatory cytokines inflammatory phenotype inhibiting viral replication Innate innate immune response Innate immunity Interaction interferon interferons investigated low frequency Lung epithelial cells mechanism mononuclear cell multi-organ failure neuropilin observation Pathogenesis PBMC PD-L1 marker pDC/type I IFN axis Peripheral blood pharmacological strategy phenotype plasmacytoid dendritic cell plasmacytoid dendritic cells pro-inflammatory cytokine pro-inflammatory cytokines producing productive viral replication progression protective role regulate Regulation released responsible resulting SARS-CoV-2 SARS-CoV-2 infected subject SARS-COV-2 infection SARS-CoV-2 pandemic secreted secretion serum severe COVID-19 Severe COVID-19 Infection severe COVID-19 patients stratified the cytokine storm the interferon tissue damage TLR7/8 type I type I and III IFNs type I and III interferons Type I IFN type I IFN producing cells Viral viral replication Viral resistance virus viruses
[DOI] 10.1371/journal.ppat.1009878 PMC 바로가기 [Article Type] Research Article